Loading...
HLS Therapeutics Inc.
HLTRF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$3.57
$-0.03(-0.83%)
HLS Therapeutics Inc. (HLTRF) Financial Performance & Income Statement Overview
Review HLS Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-10.23%
↓ 10.23%
Operating Income Growth
25.73%
↑ 25.73%
Net Income Growth
28.61%
↑ 28.61%
Operating Cash Flow Growth
-49.31%
↓ 49.31%
Operating Margin
-11.10%
↓ 11.10%
Gross Margin
72.74%
↑ 72.74%
Net Profit Margin
-31.68%
↓ 31.68%
ROE
-23.97%
↓ 23.97%
ROIC
-4.84%
↓ 4.84%
HLS Therapeutics Inc. (HLTRF) Income Statement & Financial Overview
Review HLS Therapeutics Inc.'s (HLTRF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $15.54M | $14.09M | $14.52M | $12.42M |
| Cost of Revenue | $2.69M | $2.23M | $8.16M | $7.66M |
| Gross Profit | $12.86M | $11.85M | $6.36M | $4.76M |
| Gross Profit Ratio | $0.83 | $0.84 | $0.44 | $0.38 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $6.18M | $6.80M | $6.96M | $8.21M |
| Operating Expenses | $15.90M | $16.75M | $6.96M | $8.21M |
| Total Costs & Expenses | $18.58M | $18.99M | $10.69M | $15.87M |
| Interest Income | $34984.00 | $49000.00 | $97000.00 | $137000.00 |
| Interest Expense | $2.30M | $2.45M | $2.71M | $2.63M |
| Depreciation & Amortization | $5.43M | $5.51M | $5.86M | $5.89M |
| EBITDA | $4.79M | $3.06M | $3.83M | $2.40M |
| EBITDA Ratio | $0.31 | $0.22 | $0.26 | $0.19 |
| Operating Income | -$3.04M | -$4.90M | $3.83M | -$3.45M |
| Operating Income Ratio | -$0.20 | -$0.35 | $0.26 | -$0.28 |
| Other Income/Expenses (Net) | $102000.00 | $0.00 | -$5.44M | -$2.68M |
| Income Before Tax | -$2.94M | -$4.90M | -$1.61M | -$6.11M |
| Income Before Tax Ratio | -$0.19 | -$0.35 | -$0.11 | -$0.49 |
| Income Tax Expense | $85000.00 | -$59000.00 | $4.08M | -$28870.00 |
| Net Income | -$3.02M | -$4.84M | -$5.68M | -$6.08M |
| Net Income Ratio | -$0.19 | -$0.34 | -$0.39 | -$0.49 |
| EPS | -$0.09 | -$0.15 | -$0.18 | -$0.19 |
| Diluted EPS | -$0.09 | -$0.15 | -$0.18 | -$0.19 |
| Weighted Avg Shares Outstanding | $31.79M | $31.79M | $31.83M | $31.94M |
| Weighted Avg Shares Outstanding (Diluted) | $31.79M | $31.79M | $31.83M | $31.94M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan